Icon

Firdapse - (10 mg; Tablet, Oral)

Amifampridine Phosphate Catalyst pharma
10 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
FIRDAPSE is a potassiumchannel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Yes
******* ****** *** * **** ** *** ****** *** **** *******, * ****** *********** ** ********. *** ********** **** ******* *** ********* *** ****. ** *** ****, ******** ******** ******* **** ******* **** ****** ***** **********. *** *********** *** ******** ******* ** *** **, ****. *** *** *** ******, ***** *** ****. *** ***** **** ********* ** *** ****.
Firdapse Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
****** ****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
**** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
***** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** ****** *** \ ********* *** **, **** ******* **** *** ****** *** ****
**** *** \ ********* *** **, **** ******* **** *** ****** *** ****
***** *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** ***** *** *********.
  2. *** **, **** : **** ******** ******** *** **** ** ***** ****-** ****** **** ******* '***, '***, '****, '****, '*** *** '***.
  3. *** **, **** : ****** (******) ******** ******** *** **** ** ***** ****-** ****** **** ******* '***, '***, '****, '****, '*** *** '***.
  4. *** **, **** : ***** ******** ******** *** **** ** ***** ****-** ****** **** ******* '***, '***, '****, '****, '*** *** '***.
  5. *** *, **** : ******** *** **** **** ****, ****** (******) *** ***** **** ************ ** ******* '***, '***, '****, '****, '*** *** '***.
  6. *** *, **** : ******** ******** ******** *** **** ** ***** ****-** ****** **** ******* '***, '***, '****, '****, '*** *** '***.
  7. *** **, **** : ******** *** **** **** ******** **** ************ ** ******* '***, '***, '****, '****, '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.